Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis

H. Buchwald, T. D. Rohde, Philip D Schneider, R. L. Varco, P. J. Blackshear

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We studied the effect of long-term intravenous heparin infusion, delivered by a self-recycling, totally implantable infusion pump developed in our laboratory, in 21 patients with recurrent thromboembolic disease. Continuous infusions were maintained in these patients from 1 to 36 months, during which pumps were refilled by percutaneous needle injection at 4- to 8-week intervals. We maintained plasma heparin levels between 0.1 and 0.3 U/ml plasma. This regimen prevented thromboembolic phenomena in all except one patient, who apparently is refractory to heparin as well as oral anticoagulant drug therapy. Marked reduction of pain and improvement of mobility were reported by several patients with vena caval ligature syndrome. No spontaneous hemorrhagic complications occurred; however, several episodes of pump site hemorrhage were associated with pump refills. Bone mineral densities measured in eight subjects after 1 year of heparin infusion [1.00 ± 0.06 (SE) gm/cm] were not significantly (P=0.5) different from baseline values (0.98 ± 0.08 gm/cm); however, osteoporosis did occur in one subject. Serum calcium, phosphorus, alkaline phosphatase, cholesterol, and triglycerides also remained unchanged in these subjects. These data suggest that continuous long-term heparin infusion is a viable therapeutic alternative in subjects with refractory thromboembolic disease.

Original languageEnglish (US)
Pages (from-to)507-516
Number of pages10
JournalSurgery
Volume88
Issue number4
StatePublished - 1980
Externally publishedYes

Fingerprint

Implantable Infusion Pumps
Venous Thrombosis
Intravenous Administration
Heparin
Venae Cavae
Recycling
Intravenous Infusions
Bone Density
Anticoagulants
Phosphorus
Osteoporosis
Needles
Ligation
Alkaline Phosphatase
Triglycerides
Cholesterol
Hemorrhage
Calcium
Drug Therapy
Pain

ASJC Scopus subject areas

  • Surgery

Cite this

Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis. / Buchwald, H.; Rohde, T. D.; Schneider, Philip D; Varco, R. L.; Blackshear, P. J.

In: Surgery, Vol. 88, No. 4, 1980, p. 507-516.

Research output: Contribution to journalArticle

@article{63acab22a77345e69da0e7417c6658b7,
title = "Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis",
abstract = "We studied the effect of long-term intravenous heparin infusion, delivered by a self-recycling, totally implantable infusion pump developed in our laboratory, in 21 patients with recurrent thromboembolic disease. Continuous infusions were maintained in these patients from 1 to 36 months, during which pumps were refilled by percutaneous needle injection at 4- to 8-week intervals. We maintained plasma heparin levels between 0.1 and 0.3 U/ml plasma. This regimen prevented thromboembolic phenomena in all except one patient, who apparently is refractory to heparin as well as oral anticoagulant drug therapy. Marked reduction of pain and improvement of mobility were reported by several patients with vena caval ligature syndrome. No spontaneous hemorrhagic complications occurred; however, several episodes of pump site hemorrhage were associated with pump refills. Bone mineral densities measured in eight subjects after 1 year of heparin infusion [1.00 ± 0.06 (SE) gm/cm] were not significantly (P=0.5) different from baseline values (0.98 ± 0.08 gm/cm); however, osteoporosis did occur in one subject. Serum calcium, phosphorus, alkaline phosphatase, cholesterol, and triglycerides also remained unchanged in these subjects. These data suggest that continuous long-term heparin infusion is a viable therapeutic alternative in subjects with refractory thromboembolic disease.",
author = "H. Buchwald and Rohde, {T. D.} and Schneider, {Philip D} and Varco, {R. L.} and Blackshear, {P. J.}",
year = "1980",
language = "English (US)",
volume = "88",
pages = "507--516",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis

AU - Buchwald, H.

AU - Rohde, T. D.

AU - Schneider, Philip D

AU - Varco, R. L.

AU - Blackshear, P. J.

PY - 1980

Y1 - 1980

N2 - We studied the effect of long-term intravenous heparin infusion, delivered by a self-recycling, totally implantable infusion pump developed in our laboratory, in 21 patients with recurrent thromboembolic disease. Continuous infusions were maintained in these patients from 1 to 36 months, during which pumps were refilled by percutaneous needle injection at 4- to 8-week intervals. We maintained plasma heparin levels between 0.1 and 0.3 U/ml plasma. This regimen prevented thromboembolic phenomena in all except one patient, who apparently is refractory to heparin as well as oral anticoagulant drug therapy. Marked reduction of pain and improvement of mobility were reported by several patients with vena caval ligature syndrome. No spontaneous hemorrhagic complications occurred; however, several episodes of pump site hemorrhage were associated with pump refills. Bone mineral densities measured in eight subjects after 1 year of heparin infusion [1.00 ± 0.06 (SE) gm/cm] were not significantly (P=0.5) different from baseline values (0.98 ± 0.08 gm/cm); however, osteoporosis did occur in one subject. Serum calcium, phosphorus, alkaline phosphatase, cholesterol, and triglycerides also remained unchanged in these subjects. These data suggest that continuous long-term heparin infusion is a viable therapeutic alternative in subjects with refractory thromboembolic disease.

AB - We studied the effect of long-term intravenous heparin infusion, delivered by a self-recycling, totally implantable infusion pump developed in our laboratory, in 21 patients with recurrent thromboembolic disease. Continuous infusions were maintained in these patients from 1 to 36 months, during which pumps were refilled by percutaneous needle injection at 4- to 8-week intervals. We maintained plasma heparin levels between 0.1 and 0.3 U/ml plasma. This regimen prevented thromboembolic phenomena in all except one patient, who apparently is refractory to heparin as well as oral anticoagulant drug therapy. Marked reduction of pain and improvement of mobility were reported by several patients with vena caval ligature syndrome. No spontaneous hemorrhagic complications occurred; however, several episodes of pump site hemorrhage were associated with pump refills. Bone mineral densities measured in eight subjects after 1 year of heparin infusion [1.00 ± 0.06 (SE) gm/cm] were not significantly (P=0.5) different from baseline values (0.98 ± 0.08 gm/cm); however, osteoporosis did occur in one subject. Serum calcium, phosphorus, alkaline phosphatase, cholesterol, and triglycerides also remained unchanged in these subjects. These data suggest that continuous long-term heparin infusion is a viable therapeutic alternative in subjects with refractory thromboembolic disease.

UR - http://www.scopus.com/inward/record.url?scp=0018930792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018930792&partnerID=8YFLogxK

M3 - Article

C2 - 7423373

AN - SCOPUS:0018930792

VL - 88

SP - 507

EP - 516

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 4

ER -